Sexual dysfunction (SD) is a troublesome adverse effect of selective serotonin reuptake inhibitors (SSRIs). A variety of mechanisms might be involved in the occurrence of SD but the exact mechanism is still not clear. Genetic variations among patients treated with SSRIs are strong determinants of intolerance and poor compliance. The present study aimed to determine the relationship between serotonin‐2A receptor (HTR2A) gene −1438A/G and 102T/C polymorphisms, serotonin transporter gene (SLC6A4) 5-HTT-linked polymorphic region (5-HTTLPR) insertion/deletion variant and brain-derived neurotrophic factor (BDNF) gene Val66Met polymorphisms and the occurrence of SD adverse effect in major depressive disorder patients treated with citalopram (CIT) or sertraline (SERT). The result from this investigation revealed that the −1438A/G and 102T/C polymorphisms appear to be associated with the SD induced by CIT. It was also demonstrated that patients receiving SERT, carrying T allele of HTR2A or L allele of 5-HTTLPR more likely to experience SD. Most important overall finding of the study is the combined effects of −1438A/G, 102T/C, and 5-HTTLPR polymorphisms. In a logistic regression model, the occurrence of SD increased with the number of risky alleles. As compared with subjects receiving SERT with few risky (≤2) alleles, those with had 5–6 alleles had an increased SD risk. After all, according to these findings, −1438A/G, 102T/C, and 5-HTTLPR polymorphisms could be considered as promising pharmacogenetic biomarkers in CIT/SERT treatment in major depressive disorder (MDD) patients to avoid the occurrence of SD.

性功能障碍（SD）是选择性5-羟色胺再摄取抑制剂（SSRIs）的不良副作用。SD的发生可能涉及多种机制，但确切机制尚不清楚。用SSRIs治疗的患者之间的遗传变异是不耐受和依从性差的重要决定因素。本研究旨在确定血清素2A受体（HTR2A）基因-1438A / G和102T / C多态性，血清素转运蛋白基因（SLC6A4）5-HTT连锁多态性区域（5-HTTLPR）插入/缺失变异与脑源性神经营养因子（BDNF西酞普兰（CIT）或舍曲林（SERT）治疗的重度抑郁症患者Val66Met基因多态性与SD不良反应的发生。这项研究的结果表明，-1438A / G和102T / C多态性似乎与CIT诱导的SD有关。还表明接受SERT的患者携带HTR2A的T等位基因或5-HTTLPR的L等位基因更有可能经历SD。该研究最重要的总体发现是−1438A / G，102T / C和5-HTTLPR多态性的综合影响。在逻辑回归模型中，SD的发生随着危险等位基因数量的增加而增加。与接受SERT的风险（≤2）等位基因很少的受试者相比，那些拥有5–6个等位基因的受试者具有更高的SD风险。毕竟，根据这些发现，在重度抑郁症（MDD）患者中，CIT / SERT治疗中-1438A / G，102T / C和5-HTTLPR多态性可被视为有希望的药物遗传学生物标记，以避免SD的发生。